Compliance, safety concerns and anxiety in patients treated with biologics for psoriasis during the COVID-19 pandemic national lockdown: a multicenter study in the Czech Republic

J Eur Acad Dermatol Venereol. 2020 Nov;34(11):e682-e684. doi: 10.1111/jdv.16771. Epub 2020 Jul 9.

Authors

F Rob¹, J Hugo², S Tivadar², P Boháč¹, S Gkalpakiotis², N Vargová¹, M Arenbergerová², J Hercogová¹

Affiliations

¹ Dermatovenereology Department, Second Faculty of Medicine, Na Bulovce Hospital, Charles University, Prague, Czech Republic.
² Dermatovenereology Department, Third Faculty of Medicine, Kralovske Vinohrady University Hospital, Charles University, Prague, Czech Republic.

No abstract available

Publication types

Letter
Multicenter Study

MeSH terms

Adolescent
Adult
Aged
Aged, 80 and over
Anxiety / epidemiology*
Biological Products / adverse effects
Biological Products / therapeutic use*
COVID-19 / epidemiology*
Czech Republic / epidemiology
Female
Humans
Immunosuppressive Agents / adverse effects
Immunosuppressive Agents / therapeutic use*
Male
Medication Adherence*
Middle Aged
Pandemics
Patient Safety*
Psoriasis / drug therapy*
Psoriasis / psychology*
SARS-CoV-2
Surveys and Questionnaires

Substances

Biological Products
Immunosuppressive Agents